Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ £¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

À´¶÷ÉúÎïmRNA±àÂëTCR-T»ñÅúÁÙ´²£¬ £¬£¬£¬£¬¾«×¼¹¥¿Ë¸Îϸ°û°© | 1·ÖÖÓÒ©ÎÅËÙÀÀ

2024-11-14
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20241111162005.jpg

Ò½ÏßÒ©ÎÅ

1. ¾ÝCDE¹ÙÍøÏÔʾ£¬ £¬£¬£¬£¬¹ãÖÝÀ´¶÷ÉúÎïÒ½Ò©ÓÐÏÞ¹«Ë¾×ÔÖ÷Ñз¢µÄ First-in-Class¡°GZL-016×¢ÉäÒº¡±»ñÁÙ´²ÊÔÑéĬʾÔÊÐí£¬ £¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÒҸβ¡¶¾Ïà¹Ø¸Îϸ°û°©¡£ ¡£¡£ÕâÊÇÈ«ÇòÊ׸öÕë¶ÔÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©µÄmRNA±àÂëTCR-Tϸ°ûÁÆ·¨¡£ ¡£¡£

2. ¿ËÈÕ¡£ ¡£¡£CDEÍø¹Ù¹«Ê¾£¬ £¬£¬£¬£¬±¦¼ÃÒ©Òµ1ÀàÐÂÒ©×¢ÉäÓÃKJ103ÄâÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ£¬ £¬£¬£¬£¬¸Ã²úÆ·ÊÊÓÃÓڸ߶ÈÖÂÃôµÄÉöÒÆÖ²»¼Õß¾ÙÐÐÍÑÃôÖÎÁÆ£¬ £¬£¬£¬£¬ÓÐÓÃɨ³ýÔ¤´æHLA¿¹ÌåÔ¤·À³¬¼±ÐÔÇãÔþ·´Ó¦¡£ ¡£¡£Æ¾Ö¤±¦¼ÃÒ©Òµ¹ûÈ»×ÊÁÏ£¬ £¬£¬£¬£¬KJ103£¨ricefidase£©ÊÇÒ»ÖÖÐÂÐ͵ÍÃâÒßÔ­ÐÔIgG½µ½âø£¬ £¬£¬£¬£¬ÈªÔ´ÓÚ·ÇÈËÖ²¡ÐÔµÄÂíÁ´Çò¾úÑÇÖÖ¡£ ¡£¡£

3. 11ÔÂ12ÈÕ£¬ £¬£¬£¬£¬¶÷»ªÒ©Òµ(002262)Ðû²¼Í¨¸æ³Æ£¬ £¬£¬£¬£¬¹«Ë¾ÓÚ¿ËÈÕÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ1À໯ѧҩƷNH160030Ƭ4¸ö¹æ¸ñµÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬ £¬£¬£¬£¬²¢½«ÓÚ½üÆÚ¿ªÕ¹ÁÙ´²ÊÔÑé¡£ ¡£¡£NH160030ÊÇÒ»¿îÊÊÓÚ¿Ú·þµÄÐÂÒ»´ú°¢Æ¬ÀàÕòÍ´Ò©£¬ £¬£¬£¬£¬Ö÷ÒªÓÃÓÚ°©Ö¢ÌÛÍ´µÄÖÎÁÆ¡£ ¡£¡£

4. 11ÔÂ12ÈÕ£¬ £¬£¬£¬£¬ÐÂŵÍþͨ¸æ£¬ £¬£¬£¬£¬¹«Ë¾¿Ø¹É×Ó¹«Ë¾Ê¯Ò©¼¯ÍžÞʯÉúÎïÖÆÒ©ÓÐÏÞ¹«Ë¾Õë¶ÔÈËÈéÍ·Áö²¡¶¾£¨HPV£©ÒýÆðµÄÏà¹Ø°©Ç°²¡±äµÄÖÎÁÆÐÔÒßÃçSYS6026»ñÅúÁÙ´²¡£ ¡£¡£SYS6026ÊÇ»ùÓÚ¹«Ë¾mRNAƽ̨×ÔÖ÷¿ª·¢µÄÊ׿îÖÎÁÆÐÔÒßÃç¡£ ¡£¡£

ͶÈÚÒ©ÊÂ

1. 11ÔÂ13ÈÕ£¬ £¬£¬£¬£¬ÅɸñÉúÎïÏò¸Û½»ËùµÝ½»ÕйÉÊ飬 £¬£¬£¬£¬ÄâÔÚÏã¸ÛÖ÷°åÉÏÊС£ ¡£¡£¹«Ë¾½¨ÉèÓÚ2008Ä꣬ £¬£¬£¬£¬ÊÇÒ»¼ÒרעÓÚ×ÔÖ÷Ñо¿¼°¿ª·¢ÂýÐÔ²¡Á¢ÒìÁÆ·¨µÄÉúÎï¼¼Êõ¹«Ë¾£¬ £¬£¬£¬£¬ÖØµã¹Ø×¢´úлÔÓÂÒÁìÓò¡£ ¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 11ÔÂ13ÈÕ£¬ £¬£¬£¬£¬µ¤Âó¸ç±¾¹þ¸ù´óѧµÄ¿ÆÑ§¼ÒÔÚNatureÔÓÖ¾ÉϽÒÏþÁËÈ¡µÃÁËÒ»Ï´´ÐÔµÄÑо¿Ð§¹û¡£ ¡£¡£ËûÃÇ·¢Ã÷ÁËÒ»ÖÖеļõ·ÊÒ©Îï°Ðµã¡ª¡ªNK2R¡£ ¡£¡£ËûÃÇ¿ª·¢µÄfirst-in-classÑ¡ÔñÐÔ³¤Ð§NK2R¼¤¶¯¼Á£¬ £¬£¬£¬£¬²»µ«ÄÜÓÐÓýµµÍʳÓû£¬ £¬£¬£¬£¬²¢ÇÒ²»»áµ¼Ö¼¡ÈâÖÊÁ¿ïÔÌ­£¬ £¬£¬£¬£¬Ò²²»»áÒýÆð¶ñÐÄ¡¢ÍÂÄæµÈ²»Á¼·´Ó¦¡£ ¡£¡£¸üÖ÷ÒªµÄÊÇ£¬ £¬£¬£¬£¬ÓëÏÖÓÐÖÎÁÆÒªÁìÏà±È£¬ £¬£¬£¬£¬Õâ¿îÒ©ÎﻹÄÜÔö½øÉíÌåÈÈÁ¿µÄÏûºÄ¡£ ¡£¡£

[1]Frederike Sass et al. NK2R control of energy expenditure and feeding

to treat metabolic diseases. Nature£¨2024£©


Ïà¹ØÐÂÎÅ
ÖйúÊ׸öTCR-Tϸ°ûÖÎÁƲúÆ·½øÈëÁÙ´²Ñо¿ÐÂµÄ½×¶ÎØ­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2022-07-11
7ÔÂ8ÈÕ£¬ £¬£¬£¬£¬ÏãÑ©ÉúÃü¿ÆÑ§¼¼Êõ£¨¹ã¶«£©ÓÐÏÞ¹«Ë¾ÓëÖÐɽ´óѧÖ×Áö·ÀÖÎÖÐÐÄÕÙ¿ªÁËϸ°ûÖÎÁƲúÆ·TAEST16001ÖÎÁÆÖ×Áö¿¹Ô­NY-ESO-1±í´ïÑôÐÔ¡¢»ùÒòÐÍΪHLA-A*02:01µÄÍíÆÚÈí×éÖ¯ÈâÁöµÄ¶àÖÐÐÄ¡¢¿ª·Å¡¢µ¥±Û¡¢IIÆÚÁÙ´²Ñо¿ÏîÄ¿Æô¶¯»á£¬ £¬£¬£¬£¬±ê¼Ç×ÅÖйúÊ׸öTCR-Tϸ°ûÖÎÁƲúÆ·½øÈëÁÙ´²Ñо¿ÐµĽ׶Ρ£ ¡£¡£
AD80ÊÇÒ»Öֶ༤øÒÖÖÆ¼Á£¬ £¬£¬£¬£¬ÔÚ¶àÖÖ¸Îϸ°û°©ÁÙ´²Ç°¶¯ÎïÄ£×ÓÖоßÓп¹Ö×Áö»îÐÔ£¬ £¬£¬£¬£¬AD80ÔÚѪ½¬Öеĺ¬Á¿Í¨¹ýÃÀ¸ß÷¾ÙÐÐLC-MS/MS²â¶¨
2023-07-06
Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models, including mouse xenografts. AD80 is highly active in a tumor xenograft model. Experimental dosing for AD80 was determined from maximum tolerated dosage (MTD) studies and pharmacokinetic (PK) analysis. Quantities of AD80 in blood plasma were determined by LC-MS/MS at Medicilon.
È«ÇòÊ׿îTCR-Tϸ°ûÁÆ·¨»ñÅúÉÏÊÐ
2024-08-02
8ÔÂ1ÈÕ£¬ £¬£¬£¬£¬AdaptimmuneÐû²¼ÆäTCR-Tϸ°ûÁÆ·¨Afami-celÒѾ­»ñµÃÃÀ¹úFDAÅú×¼ÉÏÊУ¬ £¬£¬£¬£¬ÓÃÓÚÖÎÁÆÍíÆÚ»¬Ä¤ÈâÁö¡£ ¡£¡£ÖµµÃÒ»ÌáµÄÊÇ£¬ £¬£¬£¬£¬ÕâÊÇÈ«ÇòÊ׿î»ñÅúÉÏÊеÄTCR-Tϸ°ûÁÆ·¨¡£ ¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿